A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Small Cell Lung Cancer Extensive Stage
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 170 (planned)
- Started
- Jan 29, 2026
- Main results expected
- Nov 29, 2030
- Fully finished
- Dec 30, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants Who Experience an Adverse Event (AE)
Measured over: Up to approximately 58 months
Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)
Measured over: Up to approximately 21 days
Number of Participants Who Discontinue Study Intervention Due to an AE
Measured over: Up to approximately 58 months
Objective Response Rate (ORR)
Measured over: Up to approximately 58 months
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- 2026-11-09 15:36 UTC · paperwork · other
old: null
new: null
details: {"sections":["contactsLocationsModule","statusModule"]}
Trial ID NCT07227597 · record last updated 2026-11-09 · checked 2026-11-09 15:47 UTC